摘要
抗体药物是生物技术药物研发领域中公认的研究热点。在抗体药物研制过程中,免疫原性一直是限制其临床应用的重要因素,不但严重影响其安全性和有效性,有时还会导致严重的临床后果。本文主要分析了抗体药物本身引起免疫原性的多种因素以及针对这些因素的改进方法,即通过抗体的人源化、去免疫化、糖基化修饰、抗体分子小型化和多聚体问题的改善来降低抗体药物的免疫原性。
Antibody drugs have attained blockbuster status in the biopharmaceuticals.One of the most difficulties in devel-opment of antibody drugs is immunogenicity which limits the clinical application and affects the safety and efficacy of the drugs even causes severe clinical events.In this paper,we review the causes of immunogenicity and the improvement approaches,including humanization,deimmunization,modification of glycosylation,elimination of aggregation,and so on.
出处
《中国生物制品学杂志》
CAS
CSCD
2013年第7期1043-1046,共4页
Chinese Journal of Biologicals
基金
国家973项目(2012CB724502)
关键词
抗体药物
免疫原性
Antibody drugs
Immunogenicity
